Phathom Pharmaceuticals, Inc. (PHAT)
PHAT Stock Price Chart
Explore Phathom Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze PHAT price movements and trends.
PHAT Company Profile
Discover essential business fundamentals and corporate details for Phathom Pharmaceuticals, Inc. (PHAT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Oct 2019
Employees
427.00
Website
https://www.phathompharma.comCEO
Steven L. Basta
Description
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
PHAT Financial Timeline
Browse a chronological timeline of Phathom Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.18, while revenue estimate is $73.89m.
Earnings released on 30 Apr 2026
EPS came in at -$0.37 falling short of the estimated -$0.27 by -37.04%, while revenue for the quarter reached $58.30m , beating expectations by +4.29%.
Earnings released on 26 Feb 2026
EPS came in at -$0.16 surpassing the estimated -$0.32 by +49.90%, while revenue for the quarter reached $57.58m , beating expectations by +0.72%.
Earnings released on 30 Oct 2025
EPS came in at -$0.15 surpassing the estimated -$0.30 by +50.00%, while revenue for the quarter reached $49.50m , missing expectations by -13.82%.
Earnings released on 7 Aug 2025
EPS came in at -$0.79 falling short of the estimated -$0.76 by -3.95%, while revenue for the quarter reached $39.50m , missing expectations by -15.55%.
Earnings released on 1 May 2025
EPS came in at -$1.07 falling short of the estimated -$1.06 by -0.94%, while revenue for the quarter reached $28.52m , missing expectations by -19.99%.
Earnings released on 6 Mar 2025
EPS came in at -$0.79 surpassing the estimated -$1.29 by +38.76%, while revenue for the quarter reached $29.66m , beating expectations by +2.15%.
Earnings released on 7 Nov 2024
EPS came in at -$1.32 surpassing the estimated -$1.57 by +15.92%, while revenue for the quarter reached $16.35m , missing expectations by -36.55%.
Earnings released on 8 Aug 2024
EPS came in at -$1.25 falling short of the estimated -$1.20 by -4.17%, while revenue for the quarter reached $7.32m , beating expectations by +26.06%.
Earnings released on 9 May 2024
EPS came in at -$1.42 surpassing the estimated -$1.43 by +0.70%, while revenue for the quarter reached $1.91m , missing expectations by -6.73%.
Earnings released on 7 Mar 2024
EPS came in at -$0.80 surpassing the estimated -$0.92 by +13.04%, while revenue for the quarter reached $682.00k , beating expectations by +66.34%.
Earnings released on 9 Nov 2023
EPS came in at -$0.76 surpassing the estimated -$0.95 by +20.00%.
Earnings released on 10 Aug 2023
EPS came in at -$0.84 surpassing the estimated -$0.95 by +11.58%.
Earnings released on 10 May 2023
EPS came in at -$0.89 surpassing the estimated -$1.34 by +33.58%.
Earnings released on 28 Feb 2023
EPS came in at -$1.33 surpassing the estimated -$1.50 by +11.33%.
Earnings released on 8 Nov 2022
EPS came in at -$1.32 matching the estimated -$1.32.
Earnings released on 2 Aug 2022
EPS came in at -$1.33 falling short of the estimated -$1.03 by -29.13%.
Earnings released on 10 May 2022
EPS came in at -$1.07 falling short of the estimated -$0.97 by -10.31%.
Earnings released on 1 Mar 2022
EPS came in at -$0.95 falling short of the estimated -$0.86 by -10.47%.
Earnings released on 8 Nov 2021
EPS came in at -$0.98 falling short of the estimated -$0.78 by -25.64%.
Earnings released on 10 Aug 2021
EPS came in at -$1.00 surpassing the estimated -$1.07 by +6.54%.
PHAT Stock Performance
Access detailed PHAT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
